Published in Proc Natl Acad Sci U S A on January 04, 2010
Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A (2013) 2.12
CD39 and CD73 in immunity and inflammation. Trends Mol Med (2013) 2.08
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest (2011) 1.82
Deficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host disease. Blood (2012) 1.72
CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology (2010) 1.69
Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer (2013) 1.69
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A (2013) 1.54
CD73: a novel target for cancer immunotherapy. Cancer Res (2010) 1.52
Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol (2010) 1.50
CD73 Expressed on γδ T Cells Shapes Their Regulatory Effect in Experimental Autoimmune Uveitis. PLoS One (2016) 1.44
Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med (2015) 1.42
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A (2013) 1.32
Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol (2011) 1.28
Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem (2010) 1.25
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment. Cancer Microenviron (2014) 1.24
Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol (2015) 1.22
Purinergic signalling and cancer. Purinergic Signal (2013) 1.18
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol (2013) 1.15
Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell (2014) 1.12
Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov (2015) 1.12
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood (2011) 1.09
Purinergic regulation of the immune system. Nat Rev Immunol (2016) 1.09
CD73 and adenosine generation in the creation of regulatory microenvironments. Clin Exp Immunol (2013) 1.08
Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol (2014) 1.08
The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol (2013) 1.06
Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states. J Mol Med (Berl) (2013) 1.06
An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering. Sci Signal (2013) 1.05
New insights regarding the regulation of chemotaxis by nucleotides, adenosine, and their receptors. Purinergic Signal (2012) 1.04
Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol (2014) 1.04
Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol (2012) 1.03
Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma. World J Gastroenterol (2013) 1.03
Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res (2014) 1.01
The roles of CD73 in cancer. Biomed Res Int (2014) 1.01
CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol (2012) 1.00
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J (2015) 1.00
CD73 promotes tumor growth and metastasis. Oncoimmunology (2012) 0.97
Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am J Transl Res (2014) 0.96
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med (2014) 0.96
Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia (2013) 0.96
Loss of CD73-mediated actin polymerization promotes endometrial tumor progression. J Clin Invest (2015) 0.94
The proteomic landscape of triple-negative breast cancer. Cell Rep (2015) 0.94
Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection. J Mol Med (Berl) (2014) 0.94
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell (2017) 0.94
Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin Biol Ther (2014) 0.93
A2B adenosine receptor blockade inhibits growth of prostate cancer cells. Purinergic Signal (2013) 0.91
Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer (2016) 0.90
Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy? Breast Care (Basel) (2012) 0.90
Chemotherapeutic drugs induce ATP release via caspase-gated pannexin-1 channels and a caspase/pannexin-1-independent mechanism. J Biol Chem (2014) 0.89
The double-edge sword effect of anti-CD73 cancer therapy. Oncoimmunology (2012) 0.89
Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell type. Mol Cancer (2013) 0.89
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment. Front Immunol (2016) 0.88
Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer. J Mol Med (Berl) (2013) 0.87
Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action. MAbs (2016) 0.87
Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas. Neuro Oncol (2013) 0.85
Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. Oncoimmunology (2013) 0.84
Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol Ther (2013) 0.84
CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells. J Biol Chem (2013) 0.84
Ectonucleotidases in tumor cells and tumor-associated immune cells: an overview. J Biomed Biotechnol (2012) 0.83
High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors. Mediators Inflamm (2014) 0.83
CD73 expression is dynamically regulated in the germinal center and bone marrow plasma cells are diminished in its absence. PLoS One (2014) 0.82
Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapy. Purinergic Signal (2011) 0.82
β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells. Cancer Biol Ther (2015) 0.82
The role of regulatory T cells in cancer immunology. Immunotargets Ther (2015) 0.82
Graft-versus-host disease is enhanced by selective CD73 blockade in mice. PLoS One (2013) 0.81
A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation. Oncotarget (2015) 0.80
MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma. Oncotarget (2016) 0.80
Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV. Cancer Microenviron (2014) 0.80
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev (2017) 0.80
Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis. Oncoimmunology (2014) 0.79
Growth and metastasis of B16-F10 melanoma cells is not critically dependent on host CD73 expression in mice. BMC Cancer (2014) 0.79
Immunotherapy of cancer: reprogramming tumor-immune crosstalk. Clin Dev Immunol (2012) 0.79
Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene (2016) 0.79
Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape. J Immunother Cancer (2016) 0.78
Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. JCI Insight (2017) 0.78
Requirement of NK cells for selective A2A receptor blockade to suppress CD73+ tumor metastasis. Immunotherapy (2014) 0.78
Probing biased/partial agonism at the G protein-coupled A(2B) adenosine receptor. Biochem Pharmacol (2014) 0.78
Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model. Oncotarget (2015) 0.78
Natural killer lytic-associated molecule plays a role in controlling tumor dissemination and metastasis. Front Immunol (2012) 0.78
Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. Oncotarget (2017) 0.78
A new signaling paradigm to control the prenylation and trafficking of small GTPases. Cell Cycle (2013) 0.77
NTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression. Purinergic Signal (2014) 0.77
A yeast screening method to decipher the interaction between the adenosine A2B receptor and the C-terminus of different G protein α-subunits. Purinergic Signal (2014) 0.77
A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer. Curr Opin Pharmacol (2016) 0.77
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. Front Oncol (2016) 0.77
Immune profiling and cancer post transplantation. World J Nephrol (2015) 0.77
Extracellular Adenosine Production by ecto-5'-Nucleotidase (CD73) Enhances Radiation-Induced Lung Fibrosis. Cancer Res (2016) 0.77
Ecto-5'-Nucleotidase (CD73) Deficiency in Mycobacterium tuberculosis-Infected Mice Enhances Neutrophil Recruitment. Infect Immun (2015) 0.76
Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model. Oncotarget (2016) 0.76
The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27. Oncoimmunology (2016) 0.76
Alternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5'-nucleotidase (CD73). Mol Biol Cell (2014) 0.76
Adenosine A2B Receptor: From Cell Biology to Human Diseases. Front Chem (2016) 0.76
CD73-adenosine reduces immune responses and survival in ovarian cancer patients. Oncoimmunology (2016) 0.76
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest (2017) 0.76
Extracellular purines, purinergic receptors and tumor growth. Oncogene (2016) 0.76
Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression. Oncotarget (2016) 0.75
Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases. Oncoimmunology (2017) 0.75
An in vivo screening system to identify tumorigenic genes. Oncogene (2016) 0.75
Tumor-infiltrating CD39(+)γδTregs are novel immunosuppressive T cells in human colorectal cancer. Oncoimmunology (2017) 0.75
Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73. BMC Cancer (2017) 0.75
The inflammasomes: guardians of the body. Annu Rev Immunol (2009) 12.89
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science (2006) 6.00
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov (2008) 4.76
A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A (2006) 4.25
Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med (2004) 4.16
Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest (2002) 4.05
Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol (2001) 3.75
CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat Med (2002) 3.18
5'-adenosine monophosphate is the neutrophil-derived paracrine factor that elicits chloride secretion from T84 intestinal epithelial cell monolayers. J Clin Invest (1993) 3.02
Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal (2006) 2.98
A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood (2007) 2.70
Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One (2008) 2.51
Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev (1998) 2.46
Neutrophil-derived 5'-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med (1998) 2.33
Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res (2005) 2.02
Adenosine receptors in regulation of dendritic cell differentiation and function. Blood (2008) 1.91
Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res (2008) 1.84
CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2008) 1.75
Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. J Immunol (2009) 1.68
Spatial restriction of alpha4 integrin phosphorylation regulates lamellipodial stability and alpha4beta1-dependent cell migration. J Cell Biol (2003) 1.58
Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int J Oncol (2008) 1.58
Ecto-5'-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol (2007) 1.47
Human sebaceous tumors harbor inactivating mutations in LEF1. Nat Med (2006) 1.40
Integrin-mediated protein kinase A activation at the leading edge of migrating cells. Mol Biol Cell (2008) 1.32
RNA interference of ecto-5'-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clin Exp Metastasis (2007) 1.29
Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol Cell Proteomics (2009) 1.21
Inhibition of Siah ubiquitin ligase function. Oncogene (2008) 1.20
CD73 engagement promotes lymphocyte binding to endothelial cells via a lymphocyte function-associated antigen-1-dependent mechanism. J Immunol (2000) 1.19
CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes. J Immunol (2008) 1.18
Role of estrogen receptor in the regulation of ecto-5'-nucleotidase and adenosine in breast cancer. Clin Cancer Res (2004) 1.17
Gene expression profiling of tumor xenografts: In vivo analysis of organ-specific metastasis. Int J Cancer (2003) 1.10
Selective deletion of the A1 adenosine receptor abolishes heart-rate slowing effects of intravascular adenosine in vivo. PLoS One (2009) 1.09
The role of ecto-5'-nucleotidase/CD73 in glioma cell line proliferation. Mol Cell Biochem (2008) 1.08
Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proc Natl Acad Sci U S A (2008) 1.07
Ecto-5'-nucleotidase (eN, CD73) is coexpressed with metastasis promoting antigens in human melanoma cells. Nucleosides Nucleotides Nucleic Acids (2006) 1.07
Differential ectonucleotidase expression in human bladder cancer cell lines. Urol Oncol (2009) 1.06
Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation. Br J Cancer (2004) 1.04
Adenosine upregulates CXCR4 and enhances the proliferative and migratory responses of human carcinoma cells to CXCL12/SDF-1alpha. Int J Cancer (2006) 1.02
IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier. Eur J Immunol (2008) 1.01
CD73 participates in cellular multiresistance program and protects against TRAIL-induced apoptosis. J Immunol (2008) 0.99
Evidence for the involvement of ecto-5'-nucleotidase (CD73) in drug resistance. Int J Cancer (1996) 0.99
Expression of CD73 and its ecto-5'-nucleotidase activity are elevated in papillary thyroid carcinomas. Histopathology (2006) 0.98
Combined affinity labelling and mass spectrometry analysis of differential cell surface protein expression in normal and prostate cancer cells. Oncogene (2005) 0.96
Expression of CD 73 (ecto-5'-nucleotidase) in 165 glioblastomas by immunohistochemistry and electronmicroscopic histochemistry. Anticancer Res (1999) 0.94
In vitro evaluation of adenosine 5'-monophosphate as an imaging agent of tumor metabolism. J Nucl Med (2006) 0.91
Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior. Am J Pathol (2004) 0.88
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
NKT cells: what's in a name? Nat Rev Immunol (2004) 7.84
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Immune surveillance of tumors. J Clin Invest (2007) 5.04
IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med (2010) 4.65
CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol (2006) 4.48
The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med (2010) 4.04
Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol (2002) 3.96
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23
Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol (2002) 3.20
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A (2008) 3.19
A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage. J Exp Med (2002) 3.13
Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol (2006) 3.04
IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol (2007) 2.99
A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation. Immunity (2005) 2.97
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med (2005) 2.83
Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol (2005) 2.77
A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med (2002) 2.73
BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med (2007) 2.70
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res (2013) 2.62
Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity (2009) 2.61
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59
Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci U S A (2008) 2.57
Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature (2009) 2.54
Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol (2003) 2.48
Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood (2005) 2.39
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med (2005) 2.32
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J Immunol (2007) 2.26
Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol (2011) 2.21
Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis. J Immunol (2008) 2.19
Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10
Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol (2005) 2.08
Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J Exp Med (2010) 2.06
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res (2011) 2.03
IL-21 induces the functional maturation of murine NK cells. J Immunol (2004) 2.00
DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med (2008) 2.00
Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol (2007) 1.97
Functional subsets of mouse natural killer cells. Immunol Rev (2006) 1.95
Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol (2010) 1.94
Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med (2012) 1.93
Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood (2009) 1.91
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 1.88
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res (2011) 1.88
Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med (2002) 1.85
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol (2007) 1.84
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood (2002) 1.83
TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood (2004) 1.83
Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res (2010) 1.82
The pre-metastatic niche: finding common ground. Cancer Metastasis Rev (2013) 1.82
Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol (2008) 1.75
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med (2004) 1.73
Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity (2009) 1.73
Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res (2010) 1.71
Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol (2001) 1.70
Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood (2011) 1.69
The influence of CD1d in postselection NKT cell maturation and homeostasis. J Immunol (2005) 1.68
Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res (2010) 1.66
A potential role for RAG-1 in NK cell development revealed by analysis of NK cells during ontogeny. Immunol Cell Biol (2009) 1.63
Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood (2005) 1.60
Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res (2012) 1.59
Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol (2010) 1.58
A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition. J Exp Med (2006) 1.56
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A (2013) 1.54
Long-term retention of mature NK1.1+ NKT cells in the thymus. J Immunol (2006) 1.53
TRAIL and its receptors as targets for cancer therapy. Cancer Sci (2004) 1.53
CD73: a potent suppressor of antitumor immune responses. Trends Immunol (2012) 1.52
Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol (2002) 1.50
Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples. Eur J Immunol (2005) 1.49
Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. J Exp Med (2007) 1.49
Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res (2012) 1.48
A semi-invariant Vα10+ T cell antigen receptor defines a population of natural killer T cells with distinct glycolipid antigen-recognition properties. Nat Immunol (2011) 1.47
Asymmetric cell division of T cells upon antigen presentation uses multiple conserved mechanisms. J Immunol (2010) 1.46
Granzyme B expression by CD8+ T cells is required for the development of experimental cerebral malaria. J Immunol (2011) 1.46
Perforin and granzymes have distinct roles in defensive immunity and immunopathology. Immunity (2006) 1.44
Antibody responses to glycolipid-borne carbohydrates require CD4+ T cells but not CD1 or NKT cells. Immunol Cell Biol (2011) 1.41
Inflammation and immune surveillance in cancer. Semin Cancer Biol (2011) 1.41
Cutting edge: TRAIL deficiency accelerates hematological malignancies. J Immunol (2005) 1.40
Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med (2004) 1.40
CD73-deficient mice are resistant to carcinogenesis. Cancer Res (2012) 1.38
Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res (2012) 1.36